Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more

PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting

In BioCentury’s latest Clinical Report: Sage misses in early Alzheimer’s, and a Phase III setback for J&J’s bladder cancer delivery device 

ODAC votes against use of PD-1 mAbs for PD-L1 low gastric, esophageal cancers

April opinions also include earlier-line use of J&J’s Rybrevant and BMS’s Opdivo

Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more products

Johnson & Johnson presents trove of data on bispecific antibody Rybrevant at the ESMO 2023 Congress

Effectively non-operational since 2019, the biotech could receive milestones tied to Onivyde and pay them out as a dividend